The Georgian biopharmaceutical company BioChimPharm (BCP) has completed the modernisation of its historic Bacteriophage (Phage) manufacturing factory – a two-year investment project worth €6 million and implemented with support from the EU, the EBRD, FAO and the Ministry of Economy and Sustainable Development of Georgia.
As a result, BioChimPharm has converted the plant to comply with EU GMP (Good Manufacturing Practice) guidelines, an accepted standard in the European Union. The company also plans to apply for GMP certification in the coming months.
“We hope that this success will be an inspiration for other companies to scale up knowledge-intensive and high value-added production in Georgia,” said Ambassador Pawel Herczycnski during his visit to the factory.
“The production of phage preparations and the phage therapy are still a novelty for most of the countries around the world. Millions of people still do not have access to phages, leaving patients vulnerable towards antibiotic-resistant infections,” explained Rati Golijashvili, the general manager of BioChimPharm. “With this project, the Company is increasing its production capacity and export area, thus making phages available for millions of patients across the globe.”
Find out more
More campaign pages:
Interested in the latest news and opportunities?
This website is managed by the EU-funded Regional Communication Programme for the Eastern Neighbourhood ('EU NEIGHBOURS east’), which complements and supports the communication of the Delegations of the European Union in the Eastern partner countries, and works under the guidance of the European Commission’s Directorate-General for Neighbourhood Policy and Enlargement Negotiations, and the European External Action Service. EU NEIGHBOURS east is implemented by a B&S Europe-led consortium. It is part of the larger Neighbourhood Communication Programme (2020-2024) for the EU's Eastern and Southern Neighbourhood, which also includes 'EU NEIGHBOURS south’ project that runs the EU Neighbours portal.